🟢 Vertex Pharmaceuticals is trading 6.8% up today after revenue beat and raised 2026 guidance

Vertex Pharmaceuticals is trading 6.8% up at $529.95 following continued positive investor response to its August 3 second-quarter report.

• Revenue increased 12% to $3.33 billion, exceeding expectations of $3.23 billion.
• Management raised 2026 revenue guidance to $13.1-$13.2 billion from $12.95-$13.1 billion.
• The company-specific move contrasts with slightly weaker major U.S. indices on August 10; shares closed at $496.07 on August 7, up 2.49%, before extending their advance during August 10 trading.